Lyophilized Bacterial Consortium Compositions for Allergic Disease Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatment options for allergic diseases such as asthma and allergic dermatitis, with existing treatments having variable efficacy and significant side effects, posing a major public health challenge, especially in pediatric populations.
Innovation Solution
Pharmaceutical compositions comprising a purified bacterial population of Akkermansia sp., Faecalibacterium sp., and Lactobacillus sp., combined with a cryoprotectant and antioxidant, formulated into oral dosage forms to modulate the gut microbiome and reduce the incidence of allergic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care treatments are used for allergic diseases, then symptoms are managed, but efficacy is variable and serious side effects occur
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12) as intermediary agents that mediate the treatment effect through gut microbiome modulation. These probiotics serve as a biological mediator that reduces IgE levels and allergic symptoms without the harmful side effects of conventional medications, thereby resolving the contradiction between effective treatment and avoidance of side effects
Solution Approach 2:
The patent changes the treatment parameter from pharmacological intervention to probiotic supplementation, fundamentally altering the mechanism of action. By administering specific probiotic strains that colonize the gut and modulate the immune system, the treatment achieves reliable efficacy through biological regulation rather than chemical suppression, eliminating side effects while maintaining therapeutic benefit
2Adaptability or versatility
If existing treatments are used for allergic diseases, then symptoms are managed, but treatment options are limited and costs are high
Solution Approach 1:
The patent employs probiotic supplements as affordable, short-term therapeutic interventions that can be easily administered and discontinued. These probiotic products are significantly cheaper than long-term pharmacological treatments or immunotherapy, providing a cost-effective treatment option that expands accessibility while maintaining versatility in treatment approaches
Solution Approach 2:
The patent segments the treatment approach by targeting the gut microbiome as a distinct therapeutic pathway separate from conventional allergen-specific immunotherapy or pharmacotherapy. This segmentation creates a new, versatile treatment category that can be combined with or used independently from existing therapies, expanding treatment options while reducing overall treatment costs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce the incidence of allergic conditions by modulating the gut microbiome, offering a promising treatment for allergic diseases with improved efficacy and reduced side effects.
Implementation Method 1
a cryoprotectant
Implementation Method 2
an antioxidant
Implementation Method 3
the bacterial population is lyophilized
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.